News - Viread


Current filters:


Popular Filters

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India


US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

Gilead and Teva settle Viread patent litigation


US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

FDA backs Gilead’s Viread for children


The US Food and Drug Administration has approved US biotech firm Gilead Sciences (Nasdaq: GILD) Viread…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationViread

New research shows Gilead’s ARVs prevent HIV infection in heterosexuals


Results from two African studies of pre-exposure prophylaxis, or PrEP, released yesterday well ahead…

Anti-viralsGilead SciencesPharmaceuticalResearchTruvadaViread

Gilead to boost HIV/hep B drug access via link with Medicine Patent Pool


The Medicines Patent Pool (which was set up in 2010 by UNITAID)revealed this morning that it has entered…

Anti-viralscobicistatelvitegravirEmtrivaGilead SciencesMarkets & MarketingPharmaceuticalViread

Back to top